Abstract:Exosome-based liquid biopsy holds great potential in monitoring tumor progression. Current exosome detection biosensors rely on signal amplification strategies to improve sensitivity; however, these strategies pay little attention to manipulating the number of signal reporters, limiting the rational optimization of the biosensors. Here, we have developed a modularized surface-enhanced Raman spectroscopy (SERS) labeling strategy, where each Raman reporter is coupled with lysine as a signal-lysine module, and thus the number of Raman reporters can be precisely controlled by the modularized solid-phase peptide synthesis. Using this strategy, we screened out an optimum Raman biosensor for ultrasensitive exosome detection, with the limit of detection of 2.4 particles per microliter. This biosensor enables a successful detection of the tumor with an average diameter of approximately 3.55 mm, and thus enables successful surveillance of the postoperative tumor recurrence in mice models and distinguishing cancer patients from healthy subjects. Our work provides a de novo strategy to precisely amplify signals toward a myriad of biosensor-related medical applications.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acssensors.1c00890.Experimental details; preparation and characterization of exosomes (Figure S1); preparation and characterization of compound 1 (Figure S2); characterization of the EpCAM aptamer carrying single Raman reporter (Figure S3); detection of A549 cells derived exosomes by SERS EpCAM-aptasensors carrying single Raman reporter and SERS random sequence-sensors carrying single Raman reporter (Figure S4); mass spectra of signal amplified parts carrying (a) 5, (b) 8, and (c) 10 Raman reporters (Figure S5); gel electrophoresis image for EpCAM aptamer carrying eight Raman reporters (Figure S6); quantitative analysis of A549 cell-derived exosomes by ELISA (Figure S7); linear range of exosome detection in plasma by SERS EpCAM-aptasensors carrying eight Raman reporters (Figure S8); stability of the SERS EpCAM-aptasensors for plasma exosome detection (6.00 × 107/mL) in three consecutive weeks (Figure S9); and correlation of the SERS signal with the tumor size of NSCLC mice models (Figure S10). Tables S1–S5 (PDF)This article has not yet been cited by other publications.

Multi-targeted nanoarrays for early broad-spectrum detection of lung cancer based on blood biopsy of tumor exosomes

A Point-of-care Testing System with Love-wave Sensor and Immunogold Staining Enhancement for Early Detection of Lung Cancer

Accurate Cancer Diagnosis and Stage Monitoring Enabled by Comprehensive Profiling of Different Types of Exosomal Biomarkers: Surface Proteins and Mirnas

Microfluidic-based exosome isolation and highly sensitive aptamer exosome membrane protein detection for lung cancer diagnosis

Rapid Isolation and Multiplexed Detection of Exosome Tumor Markers Via Queued Beads Combined with Quantum Dots in a Microarray

Thermophoretic Aggregation Imaging of Tumor-Derived Exosomes by CRISPR-Cas13a-Based Nanoprobes

Combined SERS Microfluidic Chip with Gold Nanocone Array for Effective Early Lung Cancer Prognosis in Mice Model

Portable Aptasensor Based on Parallel Rolling Circle Amplification for Tumor‐Derived Exosomes Liquid Biopsy

All-in-one nanoflare biosensor combined with catalyzed hairpin assembly amplification for in situ and sensitive exosomal miRNA detection and cancer classification

An easy-operation aptasensor for simultaneous detection of multiple tumor-associated exosomal proteins based on multicolor fluorescent DNA nanoassemblies

Cancer Liquid Biopsy Using Integrated Microfluidic Exosome Analysis Platforms

Dual Tumor Exosome Biomarker Co-recognitions Based Nanoliquid Biopsy for the Accurate Early Diagnosis of Pancreatic Cancer

Target proteins-regulated DNA nanomachine-electroactive substance complexes enable separation-free electrochemical detection of clinical exosome

Ultrasensitive Exosome Detection by Modularized SERS Labeling for Postoperative Recurrence Surveillance

CRISPR/Cas12a and aptamer-chemiluminescence based analysis for the relative abundance determination of tumor-related protein positive exosomes for breast cancer diagnosis

Programmable DNA-Fueled Electrochemical Analysis of Lung Cancer Exosomes

Machine learning-based exosome profiling of multi-receptor SERS sensors for differentiating adenocarcinoma in situ from early-stage invasive adenocarcinoma

An integrative microfluidic device for isolation and ultrasensitive detection of lung cancer-specific exosomes from patient urine

Visual dual-mode aptasensor for non-small cell lung cancer exosome detection via HRP self-coupling enhanced oxidized iridium nanoparticle aggregation

Recent advances in nanotechnology-enabled biosensors for detection of exosomes as new cancer liquid biopsy

Exosome as non-invasive prognostic and diagnostic biomarker and nanovesicle for targeted therapy of non-small cell lung carcinoma